Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis

Basit Öğe Kaydı
dc.contributor.authorSakin, A.
dc.contributor.authorSahin, S.
dc.contributor.authorSakin, A.
dc.contributor.authorAtci, M.M.
dc.contributor.authorYasar, N.
dc.contributor.authorArici, S.
dc.contributor.authorGeredeli, C.
dc.date.accessioned2024-09-29T16:22:30Z
dc.date.available2024-09-29T16:22:30Z
dc.date.issued2020
dc.departmentKarabük Üniversitesien_US
dc.description.abstractPurpose: This study aimed to assess the effect of pretreatment albumin-bilirubin (ALBI) score on treatment outcomes in pancreatic cancer (PC) patients with liver metastasis at the time of diagnosis treated with chemotherapy (CT) in the first-line setting. Methods: This was a retrospective study of 273 PC patients ?18 years of age who had liver metastasis at the time of diagnosis and received CT in the first-line. ALBI score was calculated through the following formula; [(log10 bilirubin (?mol/L)×0.66)+[albumin(g/l)×?0.0852]. Patients were stratified into 3 categories based on the ALBI score as follows; grade I:ALBI ?-2.60, grade II:-2.60<ALBI?-1.39, and grade III:ALBI>-1.39. Results: A total of 273 patients, [180 (65.9%) men and 93 (34.1%) women], were evaluated. The median age was 60 years. ALBI grade was I in 45 (16.4%) patients, II in 156 (57.1%) patients, and III in 72 (26.5%) patients. Based on the ALBI grade, median progression-free survival (mPFS) was 9 months in grade I patients, 6 months in grade II patients, and 4 months in grade III patients (p=0.002), with median overall survival (mOS) durations of 12 months vs. 8 months vs. 5 months, respectively (p<0.001). Multivariate analysis showed that ALBI grade II (HR,1.543) or III (HR,2.260) negatively affected survival. Conclusion: A higher pretreatment ALBI grade is related to worse OS and PFS in PC patients with liver metastasis treated with a first-line CT, and therefore it can help predict the treatment outcomes in these patients. © 2020 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage1946en_US
dc.identifier.issn1107-0625
dc.identifier.issue4en_US
dc.identifier.pmid33099936en_US
dc.identifier.scopus2-s2.0-85090482674en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1941en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14619/10102
dc.identifier.volume25en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectALBI gradeen_US
dc.subjectAlbuminen_US
dc.subjectBilirubinen_US
dc.subjectLiver metastasisen_US
dc.subjectPancreatic canceren_US
dc.subjectSurvivalen_US
dc.titleAssessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu